KR102631281B1 - 재조합 인간 cd38-세포외 도메인을 포함하는 조성물, 방법 및/또는 키트 - Google Patents

재조합 인간 cd38-세포외 도메인을 포함하는 조성물, 방법 및/또는 키트 Download PDF

Info

Publication number
KR102631281B1
KR102631281B1 KR1020187017279A KR20187017279A KR102631281B1 KR 102631281 B1 KR102631281 B1 KR 102631281B1 KR 1020187017279 A KR1020187017279 A KR 1020187017279A KR 20187017279 A KR20187017279 A KR 20187017279A KR 102631281 B1 KR102631281 B1 KR 102631281B1
Authority
KR
South Korea
Prior art keywords
leu
thr
lys
val
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187017279A
Other languages
English (en)
Korean (ko)
Other versions
KR20200035194A (ko
Inventor
존 에이. 홀
피터 슈빈트
조디 베리
빈센조 파바로로
엘리자베스 부스
마테오 빈다
Original Assignee
그리폴스 다이어그노스틱 솔루션즈 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 그리폴스 다이어그노스틱 솔루션즈 인크. filed Critical 그리폴스 다이어그노스틱 솔루션즈 인크.
Priority to KR1020247002508A priority Critical patent/KR20240015159A/ko
Publication of KR20200035194A publication Critical patent/KR20200035194A/ko
Application granted granted Critical
Publication of KR102631281B1 publication Critical patent/KR102631281B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/80—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood groups or blood types or red blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/24—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a MBP (maltose binding protein)-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020187017279A 2017-08-10 2018-06-01 재조합 인간 cd38-세포외 도메인을 포함하는 조성물, 방법 및/또는 키트 Active KR102631281B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020247002508A KR20240015159A (ko) 2017-08-10 2018-06-01 재조합 인간 cd38-세포외 도메인을 포함하는 조성물, 방법 및/또는 키트

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762543788P 2017-08-10 2017-08-10
US62/543,788 2017-08-10
PCT/IB2018/053939 WO2019030581A1 (en) 2017-08-10 2018-06-01 COMPOSITIONS, METHODS AND / OR KITS COMPRISING AN EXTRACELLULAR DOMAIN OF RECOMBINANT HUMAN CD38

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020247002508A Division KR20240015159A (ko) 2017-08-10 2018-06-01 재조합 인간 cd38-세포외 도메인을 포함하는 조성물, 방법 및/또는 키트

Publications (2)

Publication Number Publication Date
KR20200035194A KR20200035194A (ko) 2020-04-02
KR102631281B1 true KR102631281B1 (ko) 2024-01-30

Family

ID=62846219

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020187017279A Active KR102631281B1 (ko) 2017-08-10 2018-06-01 재조합 인간 cd38-세포외 도메인을 포함하는 조성물, 방법 및/또는 키트
KR1020247002508A Pending KR20240015159A (ko) 2017-08-10 2018-06-01 재조합 인간 cd38-세포외 도메인을 포함하는 조성물, 방법 및/또는 키트

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020247002508A Pending KR20240015159A (ko) 2017-08-10 2018-06-01 재조합 인간 cd38-세포외 도메인을 포함하는 조성물, 방법 및/또는 키트

Country Status (18)

Country Link
US (3) US11708418B2 (https=)
EP (3) EP3587445B1 (https=)
JP (3) JP6833851B2 (https=)
KR (2) KR102631281B1 (https=)
CN (2) CN117820498A (https=)
AR (1) AR112357A1 (https=)
AU (2) AU2018313028B2 (https=)
BR (1) BR112020002636A2 (https=)
CA (1) CA3070789A1 (https=)
EA (1) EA202090265A1 (https=)
ES (2) ES2911243T3 (https=)
HU (1) HUE065510T2 (https=)
MX (3) MX2020001489A (https=)
PL (1) PL3587445T3 (https=)
PT (1) PT3587445T (https=)
TW (1) TW201910349A (https=)
UY (1) UY37757A (https=)
WO (1) WO2019030581A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE065510T2 (hu) * 2017-08-10 2024-05-28 Grifols Diagnostic Solutions Inc Immunglobulin Fc-régiót és poli-His domént tartalmazó oligomerizációs címke
US11746140B2 (en) * 2018-02-20 2023-09-05 F. Hoffman-La Roche Ag Composition comprising recombinant GPlbα receptor protein
CN112048019B (zh) * 2019-06-06 2023-05-09 鲁南制药集团股份有限公司 抗人cd47单克隆抗体
CN116635420A (zh) * 2020-09-10 2023-08-22 英创远达制药公司 血液筛查方法
KR20230066404A (ko) 2020-09-10 2023-05-15 카시 파마슈티컬스, 인코포레이티드 혈액 스크리닝 방법
CN112285361B (zh) * 2020-09-27 2023-12-05 中国人民解放军空军军医大学 排除抗-cd38单克隆抗体药物对抗人球蛋白检测干扰的试剂
CN114917413B (zh) * 2022-06-14 2023-04-28 健诺维(成都)生物科技有限公司 一种负载重组多肽的羊膜及其制备方法
WO2024172419A1 (ko) * 2023-02-16 2024-08-22 주식회사 디엔티 Cd38 또는 이의 단편을 포함하는 자가면역질환 치료용 조성물
CN117723749B (zh) * 2024-02-07 2024-06-04 南昌大学 基于分子粘合剂的动态光散射免疫传感检测方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994511A (en) * 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
US6506551B1 (en) * 1999-10-08 2003-01-14 North Shore - Long Island Jewish Research Institute CD38 as a prognostic indicator in B cell chronic lymphocytic leukemia
AU2001273121A1 (en) * 2000-06-30 2002-01-14 Pharmacia And Upjohn Company Recombinant staphylococcus aureus peptide deformylase
EP1697520A2 (en) * 2003-12-22 2006-09-06 Xencor, Inc. Fc polypeptides with novel fc ligand binding sites
AU2005235811B2 (en) * 2004-02-06 2011-11-03 Morphosys Ag Anti-CD38 human antibodies and uses therefor
WO2008037257A2 (en) * 2006-09-26 2008-04-03 Genmab A/S Anti-cd38 plus corticosteroids plus a non-corticosteroid chemotherapeutic for treating tumors
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
PL2185589T3 (pl) * 2007-06-01 2016-09-30 Środki wiążące receptor regionu stałego Fc immunoglobuliny
EP2573112A1 (en) * 2007-10-11 2013-03-27 The Hospital For Sick Children Modulation of sirpa - cd47 interaction for increasing human hematopoietic stem cell engraftment and compounds therefor
EP2370467B1 (en) * 2008-10-01 2016-09-07 Amgen Research (Munich) GmbH Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxc d3, igf-1rxcd3 or fapalpha xcd3 bispecific single chain antibody
DK2352763T4 (da) * 2008-10-01 2022-10-17 Amgen Res Munich Gmbh Bispecifikke enkeltkædede antistoffer med specificitet for højmolekylære målantigener
WO2010083253A2 (en) * 2009-01-14 2010-07-22 Viral Logic Systems Technology Corp. Cd47 related compositions and methods for treating immunological diseases and disorders
HUE030100T2 (en) * 2010-02-19 2017-04-28 Xencor Inc New CTLA4-IG immunoadhesins
US20130029358A1 (en) * 2010-04-01 2013-01-31 Ludwig Institute For Cancer Research Ltd. Immunodominant mhc dr52b restricted ny-eso-1 epitopes, mhc class ii monomers and multimers, and uses thereof
AU2011295715B9 (en) * 2010-09-03 2017-02-23 Abbvie Stemcentrx Llc Novel modulators and methods of use
EP2530089A1 (en) * 2011-06-03 2012-12-05 Bayer Pharma Aktiengesellschaft Neutralising prolactin receptor antibody Mat3 and its therapeutical use
KR102100388B1 (ko) * 2012-02-06 2020-04-13 인히브릭스, 인크. Cd47 항체 및 그 사용 방법
US9926373B2 (en) * 2012-04-27 2018-03-27 Novo Nordisk A/S Human CD30 ligand antigen binding proteins
CN104736174B (zh) * 2012-07-06 2019-06-14 根马布私人有限公司 具有三重突变的二聚体蛋白质
US9447193B2 (en) * 2013-03-24 2016-09-20 Development Center For Biotechnology Methods for suppressing cancer by inhibition of TMCC3
WO2015191546A2 (en) * 2014-06-10 2015-12-17 The Board Of Regents Of The University Of Texas System Adp-ribose detection reagents
WO2015195531A2 (en) * 2014-06-18 2015-12-23 Albert Einstein College Of Medicine, Inc. Syntac polypeptides and uses thereof
MA40894A (fr) * 2014-11-04 2017-09-12 Glenmark Pharmaceuticals Sa Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production
EP3221358B1 (en) * 2014-11-18 2021-07-21 Janssen Pharmaceutica, N.V. Cd47 antibodies, methods, and uses
JP6649941B2 (ja) * 2015-02-16 2020-02-19 株式会社ファーマフーズ Ｆｓｔｌ１を利用した抗がん剤・転移抑制剤およびその併用剤
US9944679B2 (en) * 2015-03-16 2018-04-17 The Catholic University Of America Authentic trimeric HIV-1 envelope glycoproteins comprising a long linker and tag
PE20171790A1 (es) * 2015-03-23 2017-12-28 Bayer Pharma AG Anticuerpos anti-ceacam6 y sus usos
WO2017043466A1 (ja) * 2015-09-08 2017-03-16 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗ＥｐｈＡ４抗体
AU2016352676A1 (en) * 2015-11-10 2018-05-31 University Medical Center Hamburg - Eppendorf ANTIGEN-binding polypeptides directed against CD38
HUE065510T2 (hu) * 2017-08-10 2024-05-28 Grifols Diagnostic Solutions Inc Immunglobulin Fc-régiót és poli-His domént tartalmazó oligomerizációs címke

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
L. Du et al. PLOS ONE. 2013, vol. 8, issue 1, e53568*
L. G. Hom & L. E. Volkman. BIOTECHNIQUES. 1998, vol. 25, no. 1, pp. 20-22*

Also Published As

Publication number Publication date
JP7289328B2 (ja) 2023-06-09
CN109790210B (zh) 2024-03-26
EP3464343A1 (en) 2019-04-10
JP2021088567A (ja) 2021-06-10
JP2019527533A (ja) 2019-10-03
MX2024008109A (es) 2024-07-19
CA3070789A1 (en) 2019-02-14
AR112357A1 (es) 2019-10-23
US11708418B2 (en) 2023-07-25
KR20240015159A (ko) 2024-02-02
JP2023041802A (ja) 2023-03-24
TW201910349A (zh) 2019-03-16
MX2024005669A (es) 2024-05-30
CN117820498A (zh) 2024-04-05
US20240132616A1 (en) 2024-04-25
EP4296680A2 (en) 2023-12-27
EP4296680A3 (en) 2024-03-20
EP3587445A1 (en) 2020-01-01
BR112020002636A2 (pt) 2020-07-28
EA202090265A1 (ru) 2020-06-05
AU2023204121B2 (en) 2026-04-23
PL3587445T3 (pl) 2024-04-29
HUE065510T2 (hu) 2024-05-28
AU2018313028B2 (en) 2023-05-25
AU2023204121A1 (en) 2023-07-20
ES2911243T3 (es) 2022-05-18
PT3587445T (pt) 2024-03-14
EP3464343B1 (en) 2022-03-23
JP6833851B2 (ja) 2021-02-24
ES2973864T3 (es) 2024-06-24
CN109790210A (zh) 2019-05-21
KR20200035194A (ko) 2020-04-02
WO2019030581A1 (en) 2019-02-14
MX2020001489A (es) 2020-03-20
EP3587445B1 (en) 2023-12-13
UY37757A (es) 2018-11-30
US20240092929A1 (en) 2024-03-21
US20210198376A1 (en) 2021-07-01
AU2018313028A1 (en) 2020-02-20
US20240228651A9 (en) 2024-07-11

Similar Documents

Publication Publication Date Title
KR102631281B1 (ko) 재조합 인간 cd38-세포외 도메인을 포함하는 조성물, 방법 및/또는 키트
Würzner et al. Inhibition of terminal complement complex formation and cell lysis by monoclonal antibodies
US20150368317A1 (en) Methods related to ctla4-fc fusion proteins
JP2025067933A (ja) 免疫チェックポイント阻害剤ｐｄ－１及びｐｄ－ｌ１に対する抗体治療をモニタリングするためのイムノアッセイ及び操作されたタンパク質
JP2023514270A (ja) 免疫グロブリン検出と関連する療法
US8461299B2 (en) Peptide capable of binding to immunoglobulin
He et al. A novel C3d-containing oligomeric vaccine provides insight into the viability of testing human C3d-based vaccines in mice
WO2013181599A2 (en) Methods related to rituximab
BR122024021835A2 (pt) Composição para ligação a um anticorpo anti-cd47, kit para investigação de biomonitoramento e ensaios de diagnóstico, métodos para: neutralização ou bloqueio da ligação de um anticorpo anti-cd47, seleção de uma unidade adequada de hemácias e remoção de anti-cd47 no plasma, soro e/ou sangue humano, e proteína de fusão.
WO2009123145A1 (ja) パラスポリン－１受容体及びその用途
WO2013181572A2 (en) Methods related to panitumumab
BR122024021803A2 (pt) Marcador de oligomerização para uma proteína de fusão recombinante, e proteína de fusão
Nedić et al. Isolated compared to membrane-bound receptors exhibit altered insulin/IGF interaction
Terasawa et al. Preferential recognition of isocitrate dehydrogenase by a rabbit monoclonal antibody (ab124797) against the C-terminal peptide of RANKL
Acton Immunoglobulins—Advances in Research and Application: 2013 Edition

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R15-X000 Change to inventor requested

St.27 status event code: A-3-3-R10-R15-oth-X000

R16-X000 Change to inventor recorded

St.27 status event code: A-3-3-R10-R16-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R15-X000 Change to inventor requested

St.27 status event code: A-3-3-R10-R15-oth-X000

R16-X000 Change to inventor recorded

St.27 status event code: A-3-3-R10-R16-oth-X000

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

X091 Application refused [patent]
AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-5-5-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000